The development of integrated predictive models that combine eGFR slope, changes in urinary albumin-to-creatinine ratio (UACR), and promising biomarkers such as TNFRs and KIM-1 holds great potential to enhance the precision of end-stage renal disease (ESRD) risk stratification. This evidence concerns the gene HAVCR1 and stage 5 chronic kidney disease.